Literature DB >> 17855373

A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.

Stéphanie Mounayar1, Sabrina Boulet, Dominique Tandé, Caroline Jan, Mathias Pessiglione, Etienne C Hirsch, Jean Féger, Marc Savasta, Chantal François, Léon Tremblay.   

Abstract

The cardinal symptoms in Parkinson's disease (PD), akinesia, rigidity and tremor, are only observed when the striatal level of dopamine is decreased by 60-80%. During the preclinical phase of PD, compensatory mechanisms are probably involved in delaying the appearance of motor symptoms. In a MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) monkey model of PD, a spontaneous recovery has been reported after initial intoxication suggesting that compensatory mechanisms are activated in this model as well. Assuming that mechanisms are similar in these phenomena, the study of recovery in monkeys following MPTP intoxication may enable identification of compensatory mechanisms involved in the preclinical phase of PD. In order to maximize the temporal similarity between PD and the MPTP model, we assessed a new progressive monkey model in which spontaneous recovery is expressed systematically and to characterize it based on (1) its behavioural features, and (2) the presence of compensatory mechanisms revealed by an immunohistological approach comparing dopaminergic and serotoninergic innervation between monkeys either exhibiting behavioural recovery or stable motor symptoms. This immunohistological study focused on the substantia nigra, striatum and pallidum, and their anatomical and functional subdivisions: sensorimotor, associative and limbic. The behavioural analysis revealed that with progressive MPTP intoxication motor symptoms were initially expressed in all monkeys. Observable recovery from these symptoms occurred in all monkeys (7/7) within 3-5 weeks after the last MPTP injection, and most exhibited a full recovery. In contrast, acute intoxication induced stable motor symptoms. Despite this obvious behavioural difference, immunohistological methods revealed that the loss of dopaminergic cell bodies in substantia nigra was substantial and similar in both MPTP-treated groups. However, quantification of fibres revealed that recovered monkeys displayed more dopaminergic and serotoninergic fibres than those with stable motor symptoms in sensorimotor and associative territories of striatum and more dopaminergic fibres in internal pallidum. This study provides a new model of PD where all monkeys expressed functional recovery from motor symptoms despite a large dopaminergic neuronal loss. The immunohistological results suggest that both dopamine and serotonin could be implicated in the compensatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855373     DOI: 10.1093/brain/awm208

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  47 in total

1.  Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter.

Authors:  Karl Strecker; Florian Wegner; Swen Hesse; Georg-Alexander Becker; Marianne Patt; Philipp M Meyer; Donald Lobsien; Johannes Schwarz; Osama Sabri
Journal:  J Neurol       Date:  2010-07-21       Impact factor: 4.849

2.  Neural correlates underlying micrographia in Parkinson's disease.

Authors:  Tao Wu; Jiarong Zhang; Mark Hallett; Tao Feng; Yanan Hou; Piu Chan
Journal:  Brain       Date:  2015-11-02       Impact factor: 13.501

3.  Patterns of striatal functional connectivity differ in early and late onset Parkinson's disease.

Authors:  Yanbing Hou; Jing Yang; Chunyan Luo; Ruwei Ou; Wei Song; Wanglin Liu; Qiyong Gong; Huifang Shang
Journal:  J Neurol       Date:  2016-07-09       Impact factor: 4.849

4.  Lateralization of brain activity pattern during unilateral movement in Parkinson's disease.

Authors:  Tao Wu; Yanan Hou; Mark Hallett; Jiarong Zhang; Piu Chan
Journal:  Hum Brain Mapp       Date:  2015-01-19       Impact factor: 5.038

5.  In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment.

Authors:  LinLin Tian; Morvarid Karimi; Chris A Brown; Susan K Loftin; Joel S Perlmutter
Journal:  Brain Res       Date:  2014-05-15       Impact factor: 3.252

6.  Basal ganglia surface morphology and the effects of stimulant medications in youth with attention deficit hyperactivity disorder.

Authors:  Loren J Sobel; Ravi Bansal; Tiago V Maia; Juan Sanchez; Luigi Mazzone; Kathleen Durkin; Jun Liu; Xuejun Hao; Iliyan Ivanov; Ann Miller; Laurence L Greenhill; Bradley S Peterson
Journal:  Am J Psychiatry       Date:  2010-07-01       Impact factor: 18.112

7.  Attention to Automatic Movements in Parkinson's Disease: Modified Automatic Mode in the Striatum.

Authors:  Tao Wu; Jun Liu; Hejia Zhang; Mark Hallett; Zheng Zheng; Piu Chan
Journal:  Cereb Cortex       Date:  2014-06-12       Impact factor: 5.357

Review 8.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

9.  MPTP Induces Systemic Parkinsonism in Middle-Aged Cynomolgus Monkeys: Clinical Evolution and Outcomes.

Authors:  Feng Yue; Sien Zeng; Rongping Tang; Guoxian Tao; Piu Chan
Journal:  Neurosci Bull       Date:  2016-10-03       Impact factor: 5.203

10.  Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion.

Authors:  Hayat Belaid; Joëlle Adrien; Elodie Laffrat; Dominique Tandé; Carine Karachi; David Grabli; Isabelle Arnulf; Stewart D Clark; Xavier Drouot; Etienne C Hirsch; Chantal François
Journal:  J Neurosci       Date:  2014-07-02       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.